Vir Biotechnology, Inc. (VIR)
10.71
+0.80
(+8.07%)
USD |
NASDAQ |
Aug 25, 16:00
10.75
+0.04
(+0.37%)
Pre-Market: 09:15
Vir Biotechnology Total Liabilities (Quarterly) : 232.31M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 232.31M |
| March 31, 2026 | 212.82M |
| December 31, 2025 | 259.65M |
| September 30, 2025 | 223.36M |
| June 30, 2025 | 245.06M |
| March 31, 2025 | 263.91M |
| December 31, 2024 | 273.20M |
| September 30, 2024 | 257.63M |
| June 30, 2024 | 235.88M |
| March 31, 2024 | 246.61M |
| December 31, 2023 | 369.85M |
| September 30, 2023 | 369.81M |
| June 30, 2023 | 433.67M |
| March 31, 2023 | 695.14M |
| December 31, 2022 | 973.85M |
| September 30, 2022 | 546.12M |
| Date | Value |
|---|---|
| June 30, 2022 | 666.98M |
| March 31, 2022 | 886.12M |
| December 31, 2021 | 619.27M |
| September 30, 2021 | 333.94M |
| June 30, 2021 | 320.26M |
| March 31, 2021 | 484.63M |
| December 31, 2020 | 201.91M |
| September 30, 2020 | 130.90M |
| June 30, 2020 | 108.46M |
| March 31, 2020 | 96.78M |
| December 31, 2019 | 88.13M |
| September 30, 2019 | 703.44M |
| June 30, 2019 | |
| March 31, 2019 | |
| December 31, 2018 | 61.64M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Caribou Biosciences, Inc. | 44.67M |
| Arrowhead Pharmaceuticals, Inc. | 1.646B |
| Oncolytics Biotech, Inc. | 13.84M |
| Sangamo Therapeutics, Inc. | 78.92M |
| Sarepta Therapeutics, Inc. | 1.661B |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 1.215B |
| Shareholders Equity (Quarterly) | 982.49M |
| Debt to Equity Ratio | 0.0949 |
| Current Ratio | 6.042 |
| Net Debt Paydown Yield | 0.03% |